ERCC1、RRM1与BRCA1蛋白联合检测在非小细胞肺癌治疗中的价值分析  

Clinical significance of ERCC1,RRM1 and BRCA1 in non-small cell lung cancer

作　　者：李铁志[1] 石彦涛[1] 高少林[1] 郑兆伟 张合林[1] 

机构地区：[1]河北医科大学第二医院胸外科,石家庄050031

出　　处：《中国医学前沿杂志（电子版）》2015年第12期36-39,共4页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

基　　金：河北省科技支撑计划项目(130202)

摘　　要：目的检测ERCC1、RRM1与BRCA1蛋白在非小细胞肺癌(NSCLC)组织中的表达水平,并制订相应化疗方案,观察其敏感性及疗效。方法使用免疫组织化学SP法联合检测NSCLC组织中ERCC1、RRM1与BRCA1蛋白水平,根据检测结果,结合3项指标水平分别与铂类、吉西他滨和紫杉类抗微管药物敏感性成反比的原则,制订相应的针对性化疗方案(观察组),并与以铂类为基础的二联标准一线化疗方案(对照组)对比,观察并分析两组患者的疾病控制率(DCR)与客观缓解率(ORR)。结果观察组55例患者中,ERCC1蛋白高表达(阳性)28例(50.91%),RRM1蛋白高表达(阳性)31例(56.36%),BRCA1蛋白高表达(阳性)25例(45.45%),未发现3项指标均为阳性的患者。观察组患者ORR和DCR均高于对照组(P<0.05)。观察组患者无进展生存时间和生存期均长于对照组(P<0.05)。结论联合检测ERCC1、RRM1与BRCA1蛋白能够为制订针对NSCLC患者的个体化化疗方案提供依据,提高治疗效果,改善患者生活质量,延长其生存期。Objective To detect the expression levels of ERCC 1, RRM1 and BRCA1 protein in non-small cell lung cancer （NSCLC）, to develop the corresponding chemotherapy regimen, and to observe its sensitivity and efficacy. Method Combined detected ofERCC1, RRM1 and BRCA1 protein levels in advanced NSCLC by immunohistochemistry SP method, according to the test results of the 3 indicators, combined with the principle that 3 indexes were inverse respectively with platinum, gemcitabine and paclitaxel anti microtubule drug＇s sensitivity, develop appropriate targeted chemotherapy regimens for observation group and platinum based first-line chemotherapy for control group. The disease control rate （DCR） and objective response rate （ORR） were compared between the two groups, and the results were analyzed. Result In observation group, there were 28 patients with high expression of ERCC1, accounting for 50.91%; high expression of RRM1 were 31 cases, accounting for 56.36%; high expression of BRCA1 were 25 cases, accounting for 45.45%; no cases with 3 positive indicators. ORR and DCR patients in observation group were higher than control group （P 〈 0.05）. Observation group patients with progression free survival time and survival time were longer than the control group （P 〈 0.05）. Conclusion Combined detected ofERCC1, RRM1 and BRCA1 in patients with NSCLC can provide a scientific basis for the chemotherapy plan, improve the therapeutic effect and the quality of life of patients, prolong the survival time of the patients.

关 键 词：非小细胞肺癌 ERCC1 RRM1 BRCA1 化疗 

分 类 号：R734.2[医药卫生—肿瘤]